News

Columnist Juliet Taylor explains how her goals and priorities dramatically shifted while living with her late husband's ALS.
Treatment with regulatory T-cells, known as Tregs, was well tolerated and seemed to reduce disease activity in a small ...
While life with ALS brings continued disease progression, columnist Kristin Neva is encouraged by signs of renewal outdoors.
The FDA cleared the launch of a Phase 1 clinical trial to test cell therapy XS-228 in people with amyotrophic lateral ...
Columnist Dagmar Munn shares the strategy that helps her get unstuck when she's not feeling motivated. Time is precious with ...
A three-drug combination worked better than any of them alone in treating ALS caused by mutations in the SOD1 gene, per a new ...
RNS60 was well tolerated when inhaled twice daily at home as part of an expanded access program (EAP) for people with ...